Galecto Completes Enrollment in Phase Ib/IIa GULLIVER-2 Trial of Its Selective, Oral Galectin-3 Inhibitor GB1211 in Liver Cirrhosis

Galecto, Inc. announced it has completed enrollment in Parts II and III of its ongoing 3-part Phase Ib/IIa trial of GB1211, GULLIVER-2, in liver cirrhosis.